NervGen Pharma Corp.

NervGen Pharma Corp. is a clinical-stage biotechnology company based in Vancouver, British Columbia, Canada. It is focused on discovering and developing a new class of drugs intended to promote repair and regeneration of the nervous system after injury or in degenerative disease. The company's lead scientific platform centers on modulation of protein kinase C (PKC) signaling — specifically the inhibition of PKC-beta — as a mechanism to overcome the inhibitory environment that blocks nerve regrowth in the central nervous system. NervGen's most advanced program is NVG-291, an experimental peptide therapeutic being studied for spinal cord injury and multiple sclerosis. The compound is designed to block the activity of a specific PKC isoform (PKC-beta) that contributes to the failure of damaged axons to regenerate. By targeting this pathway, NervGen aims to create a treatment that could restore function in patients with serious neurological damage — a therapeutic area with very few approved options. The company operates as a small, research-driven public biotech rather than a commercial-stage pharmaceutical manufacturer. It does not yet market any approved products; its value and activity revolve around preclinical research, clinical trials, regulatory interactions, and intellectual property. NervGen has been publicly listed on the TSX Venture Exchange under the ticker NVG and has also traded in the United States on the OTCQB market. As a development-stage enterprise, NervGen's business model depends on raising capital through equity financings and partnerships to fund its clinical programs. Its positioning is that of an innovative, science-first biotech pursuing a differentiated mechanism of action in the neuroscience and regenerative medicine space, with potential applications across spinal cord injury, multiple sclerosis, and possibly other central nervous system conditions.

NervGen Pharma Corp. was founded in the mid-2010s as a Vancouver-based biotechnology startup built around research into nervous system repair. The company's scientific foundation rests on the biology of protein kinase C (PKC) and, in particular, the role of the PKC-beta isoform in preventing regeneration of damaged nerve fibers in the central nervous system. This line of research emerged from academic work suggesting that blocking PKC-beta could remove a key brake on axonal regrowth. NervGen's lead asset, NVG-291, was developed as a peptide therapeutic intended to inhibit PKC-beta and thereby promote repair after injury. The company advanced NVG-291 into clinical development, initially focusing on spinal cord injury, a condition with severe unmet medical need and limited treatment options. It later expanded study interest toward multiple sclerosis, where remyelination and neurorepair are major therapeutic goals. As a development-stage company without marketed products, NervGen has relied on public equity markets to fund its research. It became a publicly traded issuer listed on the TSX Venture Exchange under the ticker NVG, and its shares have also been quoted in the United States on the OTCQB market. Over time the company has engaged in financings, clinical trial preparation, and regulatory interactions typical of a small-cap neuroscience biotech. NervGen's history is best understood as the story of a single promising scientific platform being translated toward the clinic. Its trajectory depends on the success of NVG-291 in trials, on its ability to raise capital, and on the broader interest of the pharmaceutical industry in regenerative neuroscience — a field where few therapies have reached the market.

• Founded as a Vancouver-based neuroscience biotechnology company

• Advanced lead candidate NVG-291 into clinical development for spinal cord injury

• Listed on the TSX Venture Exchange under ticker NVG

Clinical-stage neuroscience biotech pursuing first-in-class regenerative therapies via PKC-beta inhibition.

• NVG-291

  Experimental peptide therapeutic designed to inhibit PKC-beta and promote nervous system repair, studied for spinal cord injury and multiple sclerosis.

1. 1NervGen Pharma Appoints Bill Adams as Chief Financial Officerfinanznachrichten.de
2. 2NervGen Pharma Appoints Paul Brennan as President & Chief Executive Officerfinanznachrichten.de
3. 3NervGen Pharma Corp.: NervGen Pharma Announces Pricing of Overnight Marketed Equity Offeringfinanznachrichten.de
4. 4NervGen Pharma Corp.: NervGen Pharma Completes $9.2 Million Bought Deal Financingfinanznachrichten.de